Annexon, Inc.
Annexon, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 14, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 13.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 13 concluded trials, 92% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 14, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| December 31, 2026 | An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) | Trial Milestone | Phase 3 |
| July 31, 2027 | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | Trial Milestone | Phase 3 |
| July 31, 2029 | An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | Trial Milestone | Phase 3 |
Track ANNX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ANNX in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.